Immunologie - Gefahren-Management im Körper

Literatur

• 1 Bach J -F. A toll-like trigger for autoimmune disease.  Nat Med. 2005;  11 120-121
• 2 Berzofsky J A, Terabe M, Oh S, Belyakov I M, Ahlers J D, Janik J E, Morris J C. Progress on new vaccine strategies for the immunotherapy and prevention of cancer.  J Clin Invest. 2004;  113 1515-1525
• 3 Bluestone J A. Regulatory T-cell therapy: is it ready for the clinic?.  Nat Rev Immunol. 2005;  5 343-349
• 4 Calandra T. Pathogenesis of septic shock: implications for prevention and tretament.  J Chemother. 2001;  13 173-180
• 5 Curiel T J, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia J R, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis M L, Knutson K L, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.  Nat Med. 2004;  10 942-949
• 6 Decker T. Sepsis: avoiding its deadly toll.  J Clin Invest. 2004;  113 1387-1389
• 7 Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-α.  Autoimmunity. 2003;  36 511-518
• 8 Hanash A M, Levy R B. Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation.  Blood. 2005;  105 1828-1836
• 9 Lang K S, Recher M, Junt T, Navarini A A, Harris N L, Freigang S, Odermatt B, Conrad C, Ittner L M, Bauer S, Luther S A, Uematsu S, Akira S, Hengartner H, Zinkernagel R M. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease.  Nat Med. 2005;  11 138-145
• 10 Matzinger P. The danger model: a renewed sense of self.  Science. 2002;  296 301-305
• 11 Meng G, Rutz M, Schiemann M, Metzger J, Grabiec A, Schwandner R, Luppa P B, Ebel F, Busch D H, Bauer S, Wagner H, Kirschning C J. Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes.  J Clin Invest. 2004;  113 1473-1481
• 12 Möller G. Do suppressor T cells exist?.  Scand J Immunol. 1988;  27 247-250
• 13 Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses.  Annu Rev Immunol. 2004;  22 531-562
• 14 Schetter C, Vollmer J. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.  Curr Opin Drug Discover Develop. 2004;  7 204-210
• 15 Siegrist C A, Pihlgren M, Tougne C, Erfler S M, Morris M L, Al Adhami M J, Cameron D W, Cooper C L, Heathcote J, Davis H L, Lambert P H. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response.  Vaccine. 2004;  23 615-622
• 16 Takeda K, Kaisho T, Akira S. Toll-like receptors.  Annu Rev Immunol. 2003;  21 335-376
• 17 Viglietta V, Baecher-Allan C, Weiner H L, Hafler D A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.  J Exp Med. 2004;  199 971-979
• 18 von Boehmer H. Mechanisms of suppression by suppressor T cells.  Nat Immunol. 2005;  6 338-334
• 19 Wagner H. The immunobiology of the TLR9 subfamily.  Trends Immunol. 2004;  25 381-386
• 20 Waldner H, Collins M, Kuchroo V K. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmunity.  J Clin Invest. 2004;  113 990-997
• 21 Walsh P T, Taylor D K, Turka L A. Tregs and transplantation tolerance.  J Clin Invest. 2004;  114 1398-1403
• 22 Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, Fu Y -X. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.  J Exp Med. 2005;  201 779-791